Redhill Biopharma Ltd.’s stock (NASDAQ:RDHL) has soared in recent days following news that the U.S. FDA granted five years of market exclusivity for Talicia, a first-line therapy for eradication of Helicobacter pylori infection, which affects about 35% of the U.S. adult population.
The Innovative Medicines Initiative’s COMBINE (COllaboration for prevention and treatment of MDR Bacterial INfEctions) project is developing a standardized in vivo pneumonia model to test small-molecule antibiotics.
Glox Therapeutics Ltd. has raised £4.3 million (US$5.37 million) in seed funding to develop targeted therapeutics against antibiotic-resistant gram-negative bacteria. The company was founded earlier this year as a spin-out from the Universities of Glasgow and Oxford.
Traditionally developed antibiotics generally act inhibiting essential bacterial enzymes. However, new strategies are urgently needed to discover novel antibiotics against bacterial infections, such as Lyme disease caused by Borrelia burgdorferi. The chaperone high-temperature protein G (HtpG) is a nonessential bacterial protein containing a desirable druggable domain.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding $1.75 million to the University of Melbourne at the Peter Doherty Institute for Infection and Immunity to develop an oral therapeutic that restores the activity of common antibiotics used to treat community-acquired bacterial pneumonia (CABP).
Omnix Medical Ltd. is gearing up for a phase II trial next year of its novel peptide-based antibiotic OMN-6, the lead compound in a pipeline inspired by the antimicrobial strategies of insects.
Omnix Medical Ltd. is gearing up for a phase II trial next year of its novel peptide-based antibiotic OMN-6, the lead compound in a pipeline inspired by the antimicrobial strategies of insects.
Venatorx Pharmaceuticals Inc. on Aug. 15 said the U.S. FDA accepted its NDA for an intravenous antibiotic combination, cefepime-taniborbactam, to treat complicated urinary tract infection (cUTI), including acute pyelonephritis.
A chance discovery has led to a new class of antibiotics with multiple arms that interacted with the cell wall of gram-positive bacteria, inhibiting their assembly and disarming them. “It was an accidental discovery. We were using it to stain cells. We also were running evaluations of antibiotics. One of my former students came to me and said: ‘I think we have discovered something that is quite potent as an antibiotic,’” the senior author Xingyu Jiang told BioWorld.
As it nears the end of its cash runway and its lead antibiotic, Nuzyra, approaches a phase IIb readout, Paratek Pharmaceuticals Inc. agreed to be acquired by Gurnet Point Capital and Novo Holdings A/S for up to $3 per share in a deal that will take the company private.
